Merck Acquires U.K. Biotech Silence for $1.3B

Germany's Merck KGaA agreed to acquire U.K. biotech Silence Therapeutics for about $1.3 billion in cash. The deal adds divesiran, an experimental medicine for polycythemia vera, to Merck's pipeline and is slated to wrap up during the first three months of 2027.